Study Title
Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Untreated (Naïve) Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Study Details
Description:
This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
Sponsor:
Molecular Targeting Technologies, Inc.
Contacts:
Chris Pakcpak@mtarget.com
610-738-7938
Government Study Link:
NCT05475210 - Click here to see study onClinicalTrials.gov